Chen Xiu, Lu Peng, Zhou Siying, Zhang Lei, Zhao Jian-Hua, Tang Jin-Hai
Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
School of Public Health Nanjing Medical University, Nanjing, China.
Oncotarget. 2017 Feb 21;8(8):13206-13213. doi: 10.18632/oncotarget.14570.
The role of glucose transporters in cancers remains contradictory. We conducted a systematic review and meta-analysis to assess the association between overall survival and glucose transporter s (GLUTs) 1 and 3 to find an accurate prognostic biomarker.
We systematically searched the PubMed, EMbase and Medline databases for relevant published studies that were consistent with the eligible criteria up to January 2016, and calculated pooled estimated hazard ratios of GLUT-1 and -3's expressions in different cancer types and ethnic populations. Random-effects models were used to assess estimates from studies with significant heterogeneities.
Overall, 12 studies concerning GLUT 1 and 2 studies concerning GLUT 3, which involved 2008 participants when combined, were included in this analysis. We found that overexpression of GLUTs were significantly correlated to poorer survival rates (HR=1.63, 95%CI=1.09-2.44 and HR=1.89, 95%CI=1.28-2.81). In the subgroup analysis, the GLUT 1 up-regulation was correlated with negative overall survival in pancreatic cancer and gastric cancer and with better overall survival in colorectal cancer. In addition, overexpression of GLUT 1 was associated with a poorer prognosis in the Asian population, while no significance was found in the non-Asian subgroup. However, limitations do exist, which could be handled better.
A combination of GLUTs 1 and 3 might help predict malignancy of cancers and direct effective cancer therapy.
葡萄糖转运蛋白在癌症中的作用仍存在矛盾之处。我们进行了一项系统评价和荟萃分析，以评估总体生存期与葡萄糖转运蛋白（GLUTs）1和3之间的关联，从而找到一种准确的预后生物标志物。
我们系统检索了PubMed、EMbase和Medline数据库，查找截至2016年1月符合纳入标准的相关已发表研究，并计算不同癌症类型和种族人群中GLUT-1和-3表达的合并估计风险比。对于存在显著异质性的研究，采用随机效应模型评估估计值。
总体而言，本分析纳入了12项关于GLUT 1的研究和2项关于GLUT 3的研究，合并后涉及2008名参与者。我们发现GLUTs的过表达与较差的生存率显著相关（HR=1.63，95%CI=1.09-2.44；HR=1.89，95%CI=1.28-2.81）。在亚组分析中，GLUT 1上调与胰腺癌和胃癌的总体生存期呈负相关，与结直肠癌的总体生存期呈正相关。此外，GLUT 1过表达在亚洲人群中与较差的预后相关，而在非亚洲亚组中未发现显著相关性。然而，确实存在局限性，可加以更好地处理。
GLUTs 1和3的联合可能有助于预测癌症的恶性程度并指导有效的癌症治疗。
